Regional Differences in the Management of Thyroid Eye Disease: Results from an International Clinical Practice Survey of Endocrinologists.

IF 6.7 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Thyroid Pub Date : 2025-06-01 Epub Date: 2025-05-28 DOI:10.1089/thy.2024.0759
Danilo Villagelin, David S Cooper, Henry B Burch
{"title":"Regional Differences in the Management of Thyroid Eye Disease: Results from an International Clinical Practice Survey of Endocrinologists.","authors":"Danilo Villagelin, David S Cooper, Henry B Burch","doi":"10.1089/thy.2024.0759","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> Over the past several decades, there have been indications of potential shifts in the diagnostic strategies and treatment of patients with Graves' disease (GD) and thyroid eye disease (TED). The objective of this study was to evaluate current practices in managing GD when complicated by moderate-to-severe TED worldwide. <b><i>Methods:</i></b> We recently reported results from a global online survey of endocrinologists comparing the management of GD in different scenarios. The current analysis focuses on regional differences in the diagnosis and treatment of GD when complicated by TED. <b><i>Results:</i></b> A total of 1252 respondents from 85 countries completed the survey. Regarding the initial diagnostic and treatment measures, there were no differences among the various geographical regions. Regarding the treatment of moderate-to-severe TED, the use of sodium selenite was higher in Europe (66.5%) and Oceania (60%) compared to other regions (<i>p</i> < 0.001). North American respondents were more likely to recommend teprotumumab and less likely to use glucocorticoids (<i>p</i> < 0.001). When comparing the treatment options for GD in patients with TED, although prolonged use of antithyroid drugs (ATD) remained the first choice in all regions, respondents from Europe, North America, and Oceania were more likely to recommend thyroidectomy than those from other regions (<i>p</i> < 0.001). Ophthalmologists, rather than endocrinologists, would more often be responsible for prescribing advanced medical therapy for TED in North America, Oceania, and Africa, while endocrinologists would have primary responsibility in other regions of the globe. <b><i>Conclusions:</i></b> Although there are regional differences, respondents generally employ the recommended diagnostic tools, treatments, and a multidisciplinary approach suggested by current clinical practice guidelines. However, there were examples of deviations from current guidance from professional societies.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"676-683"},"PeriodicalIF":6.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223373/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/thy.2024.0759","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Over the past several decades, there have been indications of potential shifts in the diagnostic strategies and treatment of patients with Graves' disease (GD) and thyroid eye disease (TED). The objective of this study was to evaluate current practices in managing GD when complicated by moderate-to-severe TED worldwide. Methods: We recently reported results from a global online survey of endocrinologists comparing the management of GD in different scenarios. The current analysis focuses on regional differences in the diagnosis and treatment of GD when complicated by TED. Results: A total of 1252 respondents from 85 countries completed the survey. Regarding the initial diagnostic and treatment measures, there were no differences among the various geographical regions. Regarding the treatment of moderate-to-severe TED, the use of sodium selenite was higher in Europe (66.5%) and Oceania (60%) compared to other regions (p < 0.001). North American respondents were more likely to recommend teprotumumab and less likely to use glucocorticoids (p < 0.001). When comparing the treatment options for GD in patients with TED, although prolonged use of antithyroid drugs (ATD) remained the first choice in all regions, respondents from Europe, North America, and Oceania were more likely to recommend thyroidectomy than those from other regions (p < 0.001). Ophthalmologists, rather than endocrinologists, would more often be responsible for prescribing advanced medical therapy for TED in North America, Oceania, and Africa, while endocrinologists would have primary responsibility in other regions of the globe. Conclusions: Although there are regional differences, respondents generally employ the recommended diagnostic tools, treatments, and a multidisciplinary approach suggested by current clinical practice guidelines. However, there were examples of deviations from current guidance from professional societies.

甲状腺眼病管理的地区差异:来自国际内分泌学家临床实践调查的结果。
背景:在过去的几十年里,有迹象表明格雷夫斯病(GD)和甲状腺眼病(TED)患者的诊断策略和治疗可能发生变化。本研究的目的是评估目前世界范围内处理GD合并中度至重度TED的做法。方法:我们最近报告了一项全球内分泌学家在线调查的结果,比较了不同情况下GD的管理。目前的分析侧重于GD合并TED的诊断和治疗的地区差异。结果:共有来自85个国家的1252名受访者完成了调查。在初始诊断和治疗措施方面,不同地理区域之间没有差异。对于中重度TED的治疗,亚硒酸钠在欧洲(66.5%)和大洋洲(60%)的使用率高于其他地区(p < 0.001)。北美受访者更倾向于推荐teprotumumab,而不太可能使用糖皮质激素(p < 0.001)。在比较TED患者GD的治疗选择时,尽管长期使用抗甲状腺药物(ATD)仍然是所有地区的首选,但来自欧洲、北美和大洋洲的受访者比来自其他地区的受访者更倾向于推荐甲状腺切除术(p < 0.001)。在北美、大洋洲和非洲,眼科医生,而不是内分泌学家,将更多地负责为TED开出先进的药物治疗处方,而在全球其他地区,内分泌学家将主要负责。结论:尽管存在地区差异,但受访者普遍采用当前临床实践指南建议的推荐诊断工具、治疗方法和多学科方法。然而,也有偏离专业协会现行指导方针的例子。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Thyroid
Thyroid 医学-内分泌学与代谢
CiteScore
12.30
自引率
6.10%
发文量
195
审稿时长
6 months
期刊介绍: This authoritative journal program, including the monthly flagship journal Thyroid, Clinical Thyroidology® (monthly), and VideoEndocrinology™ (quarterly), delivers in-depth coverage on topics from clinical application and primary care, to the latest advances in diagnostic imaging and surgical techniques and technologies, designed to optimize patient care and outcomes. Thyroid is the leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. The Journal delivers the latest findings on topics from primary care to clinical application, and is the exclusive source for the authoritative and updated American Thyroid Association (ATA) Guidelines for Managing Thyroid Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信